• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study backs use of cannabis-based Sativex to treat MS

Study backs use of cannabis-based Sativex to treat MS

March 8, 2011
CenterWatch Staff

According to data published in the European Journal of Neurology, about half of Multiple Sclerosis (MS) patients who failed to respond to standard therapy experienced an improvement in spasticity after taking Sativex Oromucosal Spray (delta-9-tetrahydrocannabinol and cannabidiol).

 

The trial showed Sativex induced a significant improvement in scores of spasticity, spasm frequency and sleep disturbance related to spasticity compared to a placebo.  Following the four-week, single-blind therapeutic trial period involving 572 patients, Sativex was shown to have reduced the mean score for spasticity, with 48% of patients achieving a clinically meaningful improvement of ≥20% in spasticity severity. 

 

Of these responders, 241 took part in a 12-week, randomized, placebo-controlled trial phase, at the end of which the number of patients reporting an improvement in spasticity scores of ≥30% was significantly greater in the Sativex group (74%) than in the control arm (51%).

 

Sativex was approved by health regulators in the U.K. and Spain last year, but only in patients who have not responded to other medication and who show a clinically significant improvement in symptoms during a trial run of therapy.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing